SCHEMBL2291217

SCHEMBL2291217

Cc1cccc(C)c1OCc1cc(C(C)(C)C)cc(C(C)(C)C)c1C=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 2/20 0.39
ALDH1A1 P00352 5/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
NR3C1 P04150 1/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CDK4 P11802 1/20 0.33
CCNB1 P14635 1/20 0.33
CCND1 P24385 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
SCN8A Q9UQD0 2/20 0.33
GAA P10253 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CASP1 P29466 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293032 0.84 SCN2A (0.42) SCN2AALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL2294121 0.82 CYP3A4 (0.39) SCN2AALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL2286209 0.82 ALDH1A1 (0.40) SCN2AALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL2291179 0.82 SCN2A (0.36) SCN2AALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL2295181 0.80 SCN2A (0.39) SCN2AALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL2290701 0.79 MRGPRX4 (0.38) SCN2AALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL2289732 0.78 MEN1 (0.36) SCN2AALDH1A1MEN1POLBMAPT
SCHEMBL2289109 0.75 NR3C1 (0.43) SCN2AALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL2293742 0.74 NR3C1 (0.39) SCN2AALDH1A1SMN1; SMN2MEN1POLB
SCHEMBL2287477 0.73 MRGPRX4 (0.35) SCN2AALDH1A1SMN1; SMN2MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2149545-B1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2016-10-05 EP disclosed
US-7994367-B2 Method for producing benzaldehyde compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-09 US disclosed
US-20100210879-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-08-19 US disclosed
EP-2149545-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210879-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND NQO1, C9, TRPA1 SCN2A 1208/4885ALDH1A1 83/4885SMN1; SMN2 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.